Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we’re covering MJH Life Sciences’ latest acquisition expanding into the hospital and health system market, changes to Novo Nordisk’s board that have investors watching closely, and Mark Cuban’s latest partnership confirming his push to reshape prescription drug pricing.

• In business news, MJH Life Sciences has acquired BPD Healthcare, expanding its footprint into the hospital and health system space. The acquisition strengthens MJH’s position as a leading healthcare media and education platform, enhancing its ability to connect life sciences stakeholders across clinical, operational, and commercial sectors. Company leaders say the move will create new synergies for content, events, and data-driven engagement with healthcare decision-makers.
• Novo Nordisk shares dipped this week following a series of executive and board-level changes aimed at strengthening long-term governance amid record global demand for its GLP-1 portfolio. Investors are closely monitoring how the new leadership structure may shape strategy around obesity and cardiometabolic therapies, particularly as competition intensifies and regulatory scrutiny grows. Despite short-term volatility, analysts remain optimistic about Novo’s growth trajectory.
• Lastly, in the pharmacy space, Mark Cuban has confirmed a new partnership with TrumpRx through his Cost Plus Drugs platform, extending its reach to more pharmacy benefit and distribution partners. The collaboration is part of Cuban’s broader effort to deliver greater transparency and affordability in drug pricing. Analysts say the move could further disrupt traditional pharmacy benefit manager models by increasing direct-to-consumer access to lower-cost generic and specialty drugs.

From strategic acquisitions and executive shakeups to disruptive pharmacy partnerships, these developments reflect the shifting power dynamics shaping the future of healthcare and pharma commerce.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.